Huaping Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Huaping Li has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Ashenafi Bulle
Division of Oncology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, USA
1 shared publication - David D. Tran
University of Southern California 3 Division of Neuro-Oncology, Keck School of Medicine, Norris Comprehensive Cancer Center Los Angeles, California
1 shared publication - Iftikhar Ali Khawar
Division of Oncology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri
1 shared publication - Kian-Huat Lim
Division of Oncology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, USA
1 shared publication - Lin Li
Division of Oncology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri
1 shared publication - Marianna B. Ruzinova
Washington University in St. Louis 3 Department of Pathology and Immunology St. Louis, MO
1 shared publication
Latest Publications
- Open Access
- 13 May 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research
- p. OF1-OF17
Prolonged KRAS-MAPK Inhibition Induces Interferon Signaling That Promotes Cell State Transition and Confers Therapeutic Vulnerabilities
Acquired resistance limits the therapeutic efficacy of KRAS-MAPK inhibitors in pancreatic ductal adenocarcinoma (PDAC). As transcriptional plasticity and epithelial-to-mesenchymal transition (EMT) have been implicated in resistance, we sought to study the molecular mechanisms driving these changes to uncover actionable vulnerabilities. Sustained KRAS-MAPK inhibition induced interferon (IFN) and NF-κB signaling and promoted cell state change mimicking an EMT state associated with drug resistance. Network analysis identified the IFN-inducible E3 ubiquitin ligase TRIM22 as a central regulator of this response. Mechanistically, TRIM22 promoted proteasomal degradation of IκBα, resulting in sustained NF-κB and EMT program activation that coincided with a basal-like transcriptional cell state. TRIM22 expression was driven by IRF1 and IRF9 following relief of ERK-mediated transcriptional repression during pathway inhibition. EMT induction was accompanied by marked upregulation of TROP2 (TACSTD2), an NF-κB target gene enriched in basal-like PDAC cell states. Combining TROP2-directed antibody–drug conjugate sacituzumab govitecan with KRAS or ERK inhibitors significantly suppressed PDAC tumor growth in xenograft models. Overall, prolonged KRAS-MAPK inhibition activates an IFN–TRIM22–NF-κB axis that drives EMT and therapeutic resistance in PDAC, while revealing TROP2 as a clinically actionable vulnerability to overcome acquired resistance. Significance: TRIM22 drives interferon-induced EMT and NF-κB–dependent TROP2 upregulation to drive resistance to KRAS-MAPK inhibition in pancreatic cancer, which can be overcome by combining sacituzumab govitecan with KRAS-MAPK inhibitors.
- 13 May 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research
- p. OF1-OF17
Open AccessProlonged KRAS-MAPK Inhibition Induces Interferon Signaling That Promotes Cell State Transition and Confers Therapeutic Vulnerabilities
Acquired resistance limits the therapeutic efficacy of KRAS-MAPK inhibitors in pancreatic ductal adenocarcinoma (PDAC). As transcriptional plasticity and epithelial-to-mesenchymal transition (EMT) have been implicated in resistance, we sought to study the molecular mechanisms driving these changes to uncover actionable vulnerabilities. Sustained KRAS-MAPK inhibition induced interferon (IFN) and NF-κB signaling and promoted cell state change mimicking an EMT state associated with drug resistance. Network analysis identified the IFN-inducible E3 ubiquitin ligase TRIM22 as a central regulator of this response. Mechanistically, TRIM22 promoted proteasomal degradation of IκBα, resulting in sustained NF-κB and EMT program activation that coincided with a basal-like transcriptional cell state. TRIM22 expression was driven by IRF1 and IRF9 following relief of ERK-mediated transcriptional repression during pathway inhibition. EMT induction was accompanied by marked upregulation of TROP2 (TACSTD2), an NF-κB target gene enriched in basal-like PDAC cell states. Combining TROP2-directed antibody–drug conjugate sacituzumab govitecan with KRAS or ERK inhibitors significantly suppressed PDAC tumor growth in xenograft models. Overall, prolonged KRAS-MAPK inhibition activates an IFN–TRIM22–NF-κB axis that drives EMT and therapeutic resistance in PDAC, while revealing TROP2 as a clinically actionable vulnerability to overcome acquired resistance. Significance: TRIM22 drives interferon-induced EMT and NF-κB–dependent TROP2 upregulation to drive resistance to KRAS-MAPK inhibition in pancreatic cancer, which can be overcome by combining sacituzumab govitecan with KRAS-MAPK inhibitors.